Avantor, Inc.
AVTRHealthcareNASDAQMedical Instruments & Supplies · Last scanned Sep 9, 2026
Scan Results
Daily timeframeAvantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the. The company carries a $10.31B market cap, placing it firmly in the large-cap category. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips.
Market Cap
$10.31B
Beta
0.90
P/E (TTM)
—
P/E (Fwd)
17.29
EPS (TTM)
$-0.85
EPS (Fwd)
$0.88
ROE
-9.7%
ROA
2.7%
Cash
$306.8M
Total Debt
$3.70B
Free CF
$450.3M
52W Change
16.7%
Annual Financials
Cash vs Debt
Where AVTR stands vs its 150-day and 200-day moving averages
As of the August 27, 2026 close, AVTR finished 47.66% above its 150-day moving average ($9.82) and 41.46% above its 200-day moving average ($10.25). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AVTR overbought or oversold?
At the August 27, 2026 close, AVTR's RSI(14) was 72.6, in overbought territory (above 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, AVTR has $306.8M in cash with $3.70B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $450.3M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -9.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 2.7% is on the lower side, which is common in asset-heavy industries. Revenue has pulled back from $7.51B (2022) to $6.55B (2025), a 13% decline worth watching.
The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. No single metric tells the full story. Reviewing AVTR's risk profile alongside its fundamentals and technical indicators provides a more complete picture.